List of Excipients in API velpatasvir and sofosbuvir
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing velpatasvir and sofosbuvir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Gilead Sciences Inc | EPCLUSA | velpatasvir and sofosbuvir | 61958-2201 | ALCOHOL | 2034-07-30 |
| Gilead Sciences Inc | EPCLUSA | velpatasvir and sofosbuvir | 61958-2201 | CELLULOSE, MICROCRYSTALLINE | 2034-07-30 |
| Gilead Sciences Inc | EPCLUSA | velpatasvir and sofosbuvir | 61958-2201 | COPOVIDONE K25-31 | 2034-07-30 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for velpatasvir and sofosbuvir
Excipient focus: ALCOHOL
velpatasvir and sofosbuvir drug variants containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
velpatasvir and sofosbuvir drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
velpatasvir and sofosbuvir drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
velpatasvir and sofosbuvir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
velpatasvir and sofosbuvir drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
velpatasvir and sofosbuvir drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
velpatasvir and sofosbuvir drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
velpatasvir and sofosbuvir drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
velpatasvir and sofosbuvir drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
velpatasvir and sofosbuvir drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
velpatasvir and sofosbuvir drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | velpatasvir and sofosbuvir | 61958-2201 |
| Asegua Therapeutics LLC | velpatasvir and sofosbuvir | 72626-2701 |
| >Company | >Ingredient | >NDC |
velpatasvir and sofosbuvir drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch